NCT07055295View on ClinicalTrials.gov

Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Rabies
Interventions
BIOLOGICAL

Rabies Vaccine (Serum-free Vero Cell), Freeze-dried

Receiving three doses of rabies vaccine rabies vaccine manufactured by Sinovac using a three-dose PrEP schedule

BIOLOGICAL

Verorab®

Receiving three doses of marketed rabies vaccine manufactured by Sanofi using the three-dose PrEP schedule

Trial Locations (1)

Unknown

Al-Shifa Trust Eye Hospital, Rawalpindi

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY